Omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (AMPKα) in renal glomerular endothelial cells

Diabetic nephropathy (DN) is a complication of diabetes that induces the development of end-stage renal disease (ESRD). The pathogenesis of DN is reported to be closely related to the activation of the NOD-like receptor 3 (NLRP3) inflammasome in renal glomerular endothelial cells. Omarigliptin is a...

Full description

Bibliographic Details
Main Authors: Ling Li, Kelei Qian, Yuli Sun, Yong Zhao, Yun Zhou, Ying Xue, Xinyu Hong
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:Bioengineered
Subjects:
Online Access:http://dx.doi.org/10.1080/21655979.2021.1957748
id doaj-e1c611289b7046fe90220f62cddee4b9
record_format Article
spelling doaj-e1c611289b7046fe90220f62cddee4b92021-08-24T15:34:22ZengTaylor & Francis GroupBioengineered2165-59792165-59872021-01-011214805481510.1080/21655979.2021.19577481957748Omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (AMPKα) in renal glomerular endothelial cellsLing Li0Kelei Qian1Yuli Sun2Yong Zhao3Yun Zhou4Ying Xue5Xinyu Hong6Tongji Hospital, School of Medicine, Tongji UniversityShanghai Municipal Center for Disease Control and PreventionShanghai Municipal Center for Disease Control and PreventionTongji Hospital, School of Medicine, Tongji UniversityTongji Hospital, School of Medicine, Tongji UniversityTongji Hospital, School of Medicine, Tongji UniversityShanghai Municipal Center for Disease Control and PreventionDiabetic nephropathy (DN) is a complication of diabetes that induces the development of end-stage renal disease (ESRD). The pathogenesis of DN is reported to be closely related to the activation of the NOD-like receptor 3 (NLRP3) inflammasome in renal glomerular endothelial cells. Omarigliptin is a novel dipeptidyl peptidase-4 (DPP-4) inhibitor developed for the management of type II diabetes, it has been recently reported to possess a significant anti-inflammatory property. This study aims to explore the potential therapeutic effects of Omarigliptin on DN. We established an in vitro injury model in human renal glomerular endothelial cells (HrGECs) using high glucose (HG). The severe cytotoxicity and increased oxidative stress in HrGECs induced by HG were pronouncedly reversed by the introduction of Omarigliptin. Furthermore, the activated NLRP3 inflammasome and the excessive production of interleukin 18 (IL-18) and interleukin 1β (IL-1β) in HrGECs induced by incubation with HG were pronouncedly reversed by the introduction of Omarigliptin, accompanied by the activation of the AMPK/mTOR signaling pathway. After the co-administration of the adenosine monophosphate-activated protein kinase α (AMPKα) inhibitor, compound C, the protective effects of Omarigliptin against HG-induced NLRP3 inflammasome activation and production of pro-inflammatory factors were dramatically abolished. Taken together, our data revealed that Omarigliptin ameliorated HG-induced inflammation in renal glomerular endothelial cells through suppressing NLRP3 inflammasome activation mediated by AMPKα.http://dx.doi.org/10.1080/21655979.2021.1957748omarigliptinampknlrp3 inflammasomediabetic nephropathy
collection DOAJ
language English
format Article
sources DOAJ
author Ling Li
Kelei Qian
Yuli Sun
Yong Zhao
Yun Zhou
Ying Xue
Xinyu Hong
spellingShingle Ling Li
Kelei Qian
Yuli Sun
Yong Zhao
Yun Zhou
Ying Xue
Xinyu Hong
Omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (AMPKα) in renal glomerular endothelial cells
Bioengineered
omarigliptin
ampk
nlrp3 inflammasome
diabetic nephropathy
author_facet Ling Li
Kelei Qian
Yuli Sun
Yong Zhao
Yun Zhou
Ying Xue
Xinyu Hong
author_sort Ling Li
title Omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (AMPKα) in renal glomerular endothelial cells
title_short Omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (AMPKα) in renal glomerular endothelial cells
title_full Omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (AMPKα) in renal glomerular endothelial cells
title_fullStr Omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (AMPKα) in renal glomerular endothelial cells
title_full_unstemmed Omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (AMPKα) in renal glomerular endothelial cells
title_sort omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (nlrp3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (ampkα) in renal glomerular endothelial cells
publisher Taylor & Francis Group
series Bioengineered
issn 2165-5979
2165-5987
publishDate 2021-01-01
description Diabetic nephropathy (DN) is a complication of diabetes that induces the development of end-stage renal disease (ESRD). The pathogenesis of DN is reported to be closely related to the activation of the NOD-like receptor 3 (NLRP3) inflammasome in renal glomerular endothelial cells. Omarigliptin is a novel dipeptidyl peptidase-4 (DPP-4) inhibitor developed for the management of type II diabetes, it has been recently reported to possess a significant anti-inflammatory property. This study aims to explore the potential therapeutic effects of Omarigliptin on DN. We established an in vitro injury model in human renal glomerular endothelial cells (HrGECs) using high glucose (HG). The severe cytotoxicity and increased oxidative stress in HrGECs induced by HG were pronouncedly reversed by the introduction of Omarigliptin. Furthermore, the activated NLRP3 inflammasome and the excessive production of interleukin 18 (IL-18) and interleukin 1β (IL-1β) in HrGECs induced by incubation with HG were pronouncedly reversed by the introduction of Omarigliptin, accompanied by the activation of the AMPK/mTOR signaling pathway. After the co-administration of the adenosine monophosphate-activated protein kinase α (AMPKα) inhibitor, compound C, the protective effects of Omarigliptin against HG-induced NLRP3 inflammasome activation and production of pro-inflammatory factors were dramatically abolished. Taken together, our data revealed that Omarigliptin ameliorated HG-induced inflammation in renal glomerular endothelial cells through suppressing NLRP3 inflammasome activation mediated by AMPKα.
topic omarigliptin
ampk
nlrp3 inflammasome
diabetic nephropathy
url http://dx.doi.org/10.1080/21655979.2021.1957748
work_keys_str_mv AT lingli omarigliptinamelioratedhighglucoseinducednucleotideoligomerizationdomainlikereceptorprotein3nlrp3inflammasomeactivationthroughactivatingadenosinemonophosphateactivatedproteinkinaseaampkainrenalglomerularendothelialcells
AT keleiqian omarigliptinamelioratedhighglucoseinducednucleotideoligomerizationdomainlikereceptorprotein3nlrp3inflammasomeactivationthroughactivatingadenosinemonophosphateactivatedproteinkinaseaampkainrenalglomerularendothelialcells
AT yulisun omarigliptinamelioratedhighglucoseinducednucleotideoligomerizationdomainlikereceptorprotein3nlrp3inflammasomeactivationthroughactivatingadenosinemonophosphateactivatedproteinkinaseaampkainrenalglomerularendothelialcells
AT yongzhao omarigliptinamelioratedhighglucoseinducednucleotideoligomerizationdomainlikereceptorprotein3nlrp3inflammasomeactivationthroughactivatingadenosinemonophosphateactivatedproteinkinaseaampkainrenalglomerularendothelialcells
AT yunzhou omarigliptinamelioratedhighglucoseinducednucleotideoligomerizationdomainlikereceptorprotein3nlrp3inflammasomeactivationthroughactivatingadenosinemonophosphateactivatedproteinkinaseaampkainrenalglomerularendothelialcells
AT yingxue omarigliptinamelioratedhighglucoseinducednucleotideoligomerizationdomainlikereceptorprotein3nlrp3inflammasomeactivationthroughactivatingadenosinemonophosphateactivatedproteinkinaseaampkainrenalglomerularendothelialcells
AT xinyuhong omarigliptinamelioratedhighglucoseinducednucleotideoligomerizationdomainlikereceptorprotein3nlrp3inflammasomeactivationthroughactivatingadenosinemonophosphateactivatedproteinkinaseaampkainrenalglomerularendothelialcells
_version_ 1721197304868765696